Free tool
FAERS Monitor: Brytly
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220341 or its brand name (Brytly, Apraclonidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
20
Serious
12
60% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- adrenal insufficiency3
- drug intolerance3
- injection site reaction3
- vaginal infection3
- drug ineffective2
- heart rate increased2
- vision blurred2
- visual impairment2
- abdominal distension1
- abdominal pain upper1
- activities of daily living impaired1
- affective disorder1
- blood pressure increased1
- bone pain1
- cardiac disorder1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,139 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vaginal infectionSignal | 3 | 670.8 | 236.2 | 1,392 |
| adrenal insufficiencySignal | 3 | 260.1 | 91.6 | 537 |
| affective disorder | 1 | 133.8 | 19.8 | 32 |
| activities of daily living impaired | 1 | 53.1 | 7.9 | 12 |
| injection site reactionSignal | 3 | 45.9 | 16.2 | 91 |
| drug intoleranceSignal | 3 | 32.7 | 11.5 | 63 |
| heart rate increased | 2 | 21.2 | 5.7 | 21 |
| bone pain | 1 | 18.0 | 2.7 | 4 |
| visual impairment | 2 | 17.0 | 4.6 | 16 |
| vision blurred | 2 | 15.3 | 4.1 | 14 |
| cardiac disorder | 1 | 11.2 | 1.7 | 2 |
| abdominal distension | 1 | 10.1 | 1.5 | 2 |
| blood pressure increased | 1 | 6.9 | 1.0 | 1 |
| abdominal pain upper | 1 | 5.1 | 0.8 | 0 |
| drug ineffective | 2 | 1.6 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.